Key Developments: Pluristem Therapeutics Inc (PSTI.PH)

PSTI.PH on Philadelphia Stock Exchange

2.73USD
1 Jun 2015
Change (% chg)

-- (--)
Prev Close
$2.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
181
52-wk High
$3.65
52-wk Low
$2.35

Search Stocks

Latest Key Developments (Source: Significant Developments)

Pluristem gets European patent for use of cells to help treat damaged bone marrow
Wednesday, 6 May 2015 03:00am EDT 

Pluristem Therapeutics Inc:Says that it has been issued Patent No. EP2366775B1, titled 'Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy', by the European Patent Office.Says this patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem's methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.  Full Article

Pluristem Therapeutics announces positive results of trial of PLX-R18 cells for treatment of acute radiation syndrome
Wednesday, 18 Feb 2015 03:00am EST 

Pluristem Therapeutics Inc:Announced positive results of trial conducted by U.S. National Institutes of Health (NIH) to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation.Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation.  Full Article

Pluristem Therapeutics receives patent for foundational cell harvesting technology in South Africa
Tuesday, 6 Jan 2015 03:30am EST 

Pluristem Therapeutics Inc:Says it has been issued Patent No. 2013/07160, titled "Methods and Systems for Harvesting Adherent Stromal Cells", in South Africa.Patent addresses Pluristem's methods for using vibration to harvest cells grown on three-dimensional scaffolds, the harvested cells themselves, and devices developed for this process.  Full Article

Pluristem Therapeutics Inc gets Patent in Singapore for 3D Cell Expansion Technology
Monday, 1 Dec 2014 03:00am EST 

Pluristem Therapeutics Inc:Has been granted a patent in Singapore titled 'Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy.Patent No. 170761 relates to methods of expanding adherent stromal cells from human placental or adipose tissue using Pluristem's three-dimensional technology.  Full Article

Pluristem Therapeutics Inc grants patents in Australia and New Zealand
Wednesday, 12 Nov 2014 03:00am EST 

Pluristem Therapeutics Inc:Announces that it has been granted a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications.Says the patent, titled 'Adherent cells from placenta and use of same in disease treatment' has been issued in Australia, Patent No. 2010322808, and in New Zealand, Patent No. 600651.  Full Article

Pluristem Therapeutics files for secondary public offerings
Monday, 13 Oct 2014 08:00pm EDT 

Pluristem Therapeutics Inc:Offers amount of $200,000,000 to be listed on Nasdaq SmallCap Market.  Full Article

Pluristem Therapeutics Inc initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial
Tuesday, 8 Jul 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says initiation of South Korean sites in Phase II study assessing PLacental eXpanded (PLX) cells in treatment of intermittent claudication (IC).Patient screening is underway at three clinical centers, making South Korea the fourth country to participate in this randomized, double-blind, placebo-controlled Phase II trial.Says trial has been ongoing at clinical sites in the U.S., Israel and Germany with an enrollment target of 150 patients.Says In May, Pluristem received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) to use PLX cells in South Korean trials.  Full Article

Pluristem Therapeutics receives patent in russia for treatment of inflammatory bowel disease using placenta-derived cells
Thursday, 19 Jun 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says Russia's Federal Service for Intellectual Property has granted to Pluristem Patent No. 2515156 titled, "Methods of Treating Inflammatory Colon Diseases".Patent covers methods for treating ulcerative colitis or Crohn's disease using placenta-derived cells.Patent has already been issued to Pluristem in South Africa and is currently pending in several other jurisdictions.  Full Article

Pluristem Therapeutics Inc receives patent in india for cell therapy production methods and compositions
Monday, 16 Jun 2014 03:00am EDT 

Pluristem Therapeutics Inc:It has been granted Patent No. 261087 from India's Office of the Controller General of Patents.Patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company's key technology platform, its method for 3-dimensional expansion of placental and adipose (fat) derived cells.Says it also covers the composition of cells derived using this methodesigns & Trade Marks for a patent titled.  Full Article

Pluristem Therapeutics Inc updates on phase I/II clinical trial
Thursday, 29 May 2014 03:00am EDT 

Pluristem Therapeutics Inc:Says it it has enhanced its activity in the orthopedic indications for its PLacental eXpanded (PLX) cell therapies.In Jan. Pluristem announced positive results from its phase I/II clinical trial for the treatment of injured gluteal muscle after total hip arthroplasty (THA).  Full Article

Search Stocks